Glenmark launches anti-diabetes drug Remogliflozin in India
Glenmark announced the launch of its patent-protected and globally-researched sodium glucose co-transporter-2 (SGLT2) inhibitor Remogliflozin etabonate in India. The drug is indicated in the treatment of type-2 diabetes mellitus in adults.
SGL2 inhibitors are novel anti-diabetic drugs that help achieve glycemic control by acting on the SGL2 receptors in the proximal tubule of the kidney, thereby preventing renal reabsorption of glucose and promoting excretion of glucose in the urine. SGL2 drugs provide glycemic control, induce weight loss and reduce cardiovascular risk.
Glenmark is the world’s first company to launch the novel SGL2 inhibitor Remogliflozin and India is the first country to receive access to this innovative drug. Glenmark will commercialize Remogliflozin in India under the brand names 'Remo' and 'Remozen'.
Glenmark received regulatory approval for Remogliflozin etabonate 100 mg tablets after successfully completing Phase-3 clinical trials in which Remogliflozin demonstrated good efficacy and safety profile in a head-to-head comparison against Dapagliflozin.
India has an estimated 72 million adults living with diabetes, according to the International Diabetes Federation’s Diabetes, Atlas 2017. India’s diabetes market is estimated at Rs. 11,413 crore as of March 2019. The market size of SGL2 inhibitors is estimated at Rs. 574 crore as of March 2019.
On Tuesday, Glenmark was trading at Rs. 643.3 per share, down 0.33 per cent on the BSE.